SEARCH:   Advanced

Blood, 1 May 2004, Vol. 103, No. 9, pp. 3428-3430. Prepublished online as a Blood First Edition Paper on December 18, 2003; DOI 10.1182/blood-2003-07-2598. This Article Abstract Full Text (PDF) All Versions of this Article: 2003-07-2598v1 103/9/3428    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Boyer, O. Articles by Klatzmann, D. Search for Related Content PubMed PubMed Citation Articles by Boyer, O. Articles by Klatzmann, D. Related Collections Immunobiology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis Olivier Boyer, David Saadoun, Julien Abriol, Mélanie Dodille, Jean-Charles Piette, Patrice Cacoub, and David Klatzmann From the Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, CNRS/UPMC UMR 7087 and Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Paris, France.    Abstract Top Abstract Introduction Patients and methods Results Discussion References   Patients who are chronically infected with hepatitis C virus (HCV) often develop mixed cryoglobulinemia (MC), a B-cell proliferative disorder with polyclonal activation and autoantibody production. We investigated if MC is associated with a deficit of CD4+CD25+ immunoregulatory T (Treg) cells, which have been shown to control autoimmunity. Because Treg cells express higher amounts of CD25 than activated CD4+ T cells, we analyzed blood CD4+CD25high Treg cells in 69 untreated patients chronically infected with HCV. Treg cell frequency in patients without MC (8.8% ± 2.3%) or with asymptomatic MC (7.4% ± 2.1%) was comparable to that of healthy controls (7.9% ± 1.3%). In contrast, it was significantly reduced in symptomatic MC patients (2.6% ± 1.2%, P < .001) even when compared to a panel of untreated HCV- patients with different inflammatory disorders (6.2% ± 0.8%, P < .0001). In symptomatic MC patients, the purified remaining CD4+CD25+ T cells retained suppressive activity in vitro. These results, together with experimental data showing that depletion of Treg cells induces autoimmunity, suggest a major role of Treg cell deficiency in HCV-MC vasculitis and this is the first report of a quantitative Treg cell deficiency in virus-associated autoimmunity. (Blood. 2004; 103:3428-3430)    Introduction Top Abstract Introduction Patients and methods Results Discussion References   Infection with hepatitis C virus (HCV) is associated with most cases of mixed cryoglobulinemia (MC), a B-cell proliferative disorder characterized by polyclonal activation and autoantibody (aAb) production. Cryoglobulins are immunoglobulins that precipitate at cold temperature and resolubilize when rewarmed. MC is composed of different immunoglobulins, including a monoclonal component in type II and only polyclonal immunoglobulins in type III. MC may be asymptomatic or lead to clinical manifestations ranging from an MC syndrome (purpura, arthralgia, asthenia) to a more serious vasculitis with neurologic and renal involvement.1 Although MC is found in 30% to 50% of patients with chronic HCV infection, only 10% to 15% of them will develop symptomatic MC.2 The observation of T cells in the vascular infiltrates and the presence of autoantibodies together with the observation that some HLA groups confer susceptibility to MC vasculitis in HCV-infected patients suggest that autoimmune processes are implied in this virus-linked pathology.3,4 Compelling evidence now indicates that a population of CD4+CD25+ immunoregulatory T (Treg) cells plays a central role in the physiologic control of autoimmunity. Adoptive transfer of Treg-depleted T cells in mice leads to autoimmune manifestation.5 Administration of purified Treg cells allows control of autoimmune processes.6 Recently, the existence of Treg cells in healthy humans has been demonstrated7-11 and the search for their implication in autoimmune diseases is currently the object of intense investigation.12-16 The purpose of this study is to determine whether HCV-MC vasculitis is associated with a deficit in CD4+CD25+ Treg cells.    Patients and methods Top Abstract Introduction Patients and methods Results Discussion References   Patients The study was approved by institutional ethics committee and informed consent was obtained from all patients. Sixty-nine chronically HCV-infected patients (mean age, 52 years; range, 22-72 years) entered the study, of whom 22 had symptomatic MC and 26 had asymptomatic MC or aAb (rheumatoid factor, anti-DNA, antismooth muscle, antithyroperoxidase, antithyroglobulin, anticardiolipin, or lupus anticoagulant). All had histologically proven chronic active liver disease and positive HCV antibodies and RNA. They were negative for hepatitis B surface antigen and anti-HIV antibodies. MC+ patients had an MC level in their serum more than 0.05 g/L, at least at 2 determinations. Symptomatic MC was defined by serum MC associated with the triad of purpura-arthralgia-asthenia sometimes associated with renal or neurologic involvement. None of these 69 patients had received antiviral or immunosuppressive treatment for at least 6 months preceding their inclusion in the study. A population of untreated HCV- patients suffering from a panel of inflammatory disorders (Sjögren syndrome, n = 3; systemic sclerosis, n = 2; systemic vasculitis, n = 1; sepsis, n = 2; systemic lupus erythematosus, n = 1; relapsing polychondritis, n = 1) was also included. Cell separation and flow cytometry Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll density gradient and stained with combinations of the following monoclonal antibodies: Pc5-labeled anti-CD4 (13B2.2), fluorescein (FITC)-labeled anti-CD25 (B1.49.9), FITC-labeled mouse IgG2a (U7.27), or phycoerythrin (PE)-labeled mouse IgG1 isotypic control (679.1Mc7) from Coulter Immunotech (Marseille, France); PE-labeled anti-CD25 (M-A251) or FITC-labeled anti-CD62L (SK11) from BD Biosciences (San Diego, CA). Stained cells were analyzed on a FACSCalibur (Becton Dickinson, San Jose, CA). CD4+CD25+ T cells were isolated from PBMCs by a first step of negative sorting using a cocktail of hapten-conjugated CD8, CD11b, CD16, CD19, CD36, and CD56 antibodies and microbeads coupled to an antihapten monoclonal antibody (CD4+ T-cell isolation kit; Miltenyi Biotec, Bergisch Gladbach, Germany). This was followed by a step of positive selection of CD25+ cells by microbead separation (CD25 microbeads; Miltenyi Biotech), a procedure yielding to 90% or more purity as assessed by flow cytometric counting of CD4+CD25+ cells. Functional assays Costar 96-well plates (Corning, NY) were incubated with 2.5 µg/mL anti-CD3 monoclonal antibody (OKT3, Orthoclone; Jansen-Cilag, Paris, France) for 1 hour at 37°C, then for 30 minutes at 4°C, and washed. Then, 12.5 x 103 CD4+CD25+ T cells with or without 12.5 x 103 autologous responder T cells (negative fraction of CD25 sorting) were cultured in RPMI medium supplemented with 10% human AB serum in these anti-CD3-coated plates in the presence of soluble anti-CD28 (1 µg/mL, clone CD28.2; BD Biosciences Pharmingen, Le Pont de Claix, France) with or without recombinant human interleukin 2 (IL-2, 50 UI/mL; Chiron France, Suresnes, France). At day 4, 3H-thymidine (2 µCi/well [0.074 MBq/well]) was added for 16 hours before proliferation was assayed. Percent inhibition of proliferation was determined as follows: 1 - (median 3H-thymidine uptake of 1:1 CD4+CD25+:CD4+CD25- coculture/median 3H-thymidine uptake of CD4+CD25+ cells).    Results Top Abstract Introduction Patients and methods Results Discussion References   Sixty-nine chronically infected HCV patients were screened for the presence of blood Treg cells by flow cytometry. Within the CD4+ subset, Treg cells are contained in the population that displays the highest CD25 expression level.10,17 Therefore, their proportion was determined as the frequency of CD4+ T cells with the brightest anti-CD25 FITC staining (Figure 1). The frequency of Treg cells (mean ± SD) was significantly reduced in patients with symptomatic MC (2.6% ± 1.2%, n = 22, , P < .001, Mann-Whitney test) as compared to those with asymptomatic MC or aAb (7.4% ± 2.1%, n = 26, ), no MC nor aAb (8.8% ± 2.3%, n = 21, ), or healthy controls (7.9% ± 1.3%, n = 5, ). It was also significantly reduced as compared to a panel of untreated HCV- patients with different inflammatory disorders (6.2% ± 0.8%, n = 10, , P < .0001). We confirmed this Treg cell deficiency in symptomatic HCV-MC patients on a subset of patients using another CD25 antibody labeled with PE: symptomatic MC, 3.5% ± 1.1%, n = 12, P < .005; HCV- inflammation, 7.0% ± 0.9%, n = 10; asymptomatic MC or aAb, 9.9% ± 2.0%, n = 14; no MC nor aAb 9.7% ± 1.7%, n = 16; and controls, 9.3% ± 3.3%, n = 5. Because it cannot be formally excluded that the CD4+CD25+ subset also contains conventional activated CD62Llo T cells18 in addition to Treg cells that are mainly CD62L+,19 we assessed the frequency of CD62L+ within this compartment. We also found that the frequency of CD25+CD62L+ T cells within the CD4+ compartment was significantly reduced in patients with symptomatic MC (2.1% ± 1.3%, n = 12, P < .05) as compared to asymptomatic MC or aAb (4.6% ± 3.1%, n = 14), no MC nor aAb (5.7% ± 2.5%, n = 16), or controls (6.5% ± 3.2%, n = 5). Together, these results reveal a quantitative deficiency of Treg cells in symptomatic HCV-MC patients. View larger version (20K): [in this window] [in a new window]   Figure 1.. Quantitative deficiency in blood CD4+CD25+ T cells in patients with symptomatic MC. PBMCs were stained with PC5-labeled anti-CD4 together with FITC-labeled anti-CD25 or an isotypic control. The frequency of Treg cells was determined after gating on CD4+ T cells as the percentage of the brightest CD25+ population. Horizontal bar indicates the mean in each group.   Treg cells are suppressors cells that inhibit the proliferation of conventional T cells in vitro.7-9 We thus evaluated if this quantitative deficiency was associated with a functional defect. For this, we determined the capacity of immunomagnetically sorted CD4+CD25+ T cells to suppress the proliferation of autologous responder T cells on activation with anti-CD3 plus anti-CD28. At a ratio of 1:1, CD4+CD25+ suppressed the proliferation of responder cells by an average factor of 67% ± 20% in symptomatic MC patients (Figure 2A). Using this assay, the mean suppressive activity of CD4+CD25+ cells from healthy controls was 78% ± 5% (n = 3, difference not statistically significant; data not shown). The addition of exogenous IL-2 abrogated this suppression (Figure 2A), in accordance with other reports.7-11 Another property of Treg cells is their anergy, which can be reversed by IL-2.19 As expected, the sorted CD4+CD25+ population was hyporesponsive to anti-CD3 plus anti-CD28 activation (Figure 2B) as compared to their CD25- counterpart (Figure 2A), whereas addition of IL-2 reversed this anergy (Figure 2B). Together, these results indicate that the remaining CD4+CD25+ T-cell population in symptomatic MC patients contains functional Treg cells but whether or not these cells exert some control on vasculitis-associated effector T cells is unknown. View larger version (33K): [in this window] [in a new window]   Figure 2.. Functional characterization of CD4+CD25+ T cells in patients with symptomatic MC. (A) The blood CD4+CD25+ population was immunomagnetically sorted (25+) in 3 untreated patients with symptomatic MC, and assayed for its capacity to suppress anti-CD3 anti-CD28-mediated autologous responder cell (25-) proliferation at a 1:1 ratio, in the presence or absence of exogenous IL-2. Histograms represent the median of triplicates. Percent inhibition of proliferation is indicated. (B) Proliferative response of CD4+CD25+ T cells on anti-CD3 anti-CD28 activation, in the presence or absence of exogenous IL-2.      Discussion Top Abstract Introduction Patients and methods Results Discussion References   Recent studies have aimed to correlate different autoimmune diseases with Treg cell defects.12,14-16 Importantly, a Treg cell deficit due to a mutation in the FoxP3 gene has unambiguously been shown to cause aggressive autoimmunity and early death.20 The present study is the first report of a virus-linked autoimmunity associated to a quantitative Treg cell deficiency. Because Treg cell frequency in HCV-MC patients was significantly reduced as compared to patients with different inflammatory disorders, it is unlikely that it is only the feature of any systemic inflammatory response. It cannot be formally excluded that Treg cells have been recruited to sites of inflammation and consequently depleted from peripheral blood. Nevertheless, it was recently reported that accumulation of Treg cells in inflamed joints of patients with rheumatoid arthritis was not associated to a detectable reduction in the blood Treg cell count.13 A causal role for such Treg cell deficiency in MC vasculitis remains to be assessed in a prospective longitudinal study. It can be hypothesized that a Treg cell deficit may augment the helper function provided by conventional CD4+ T cells to autoantibody-secreting B cells. Along this line, we observed increased oligoclonal CD4+ T-cell expansions after IL-2 culture in symptomatic as compared to asymptomatic MC patients (not shown), suggesting that more antigen-primed helper T cells are present in the former patients. In addition, cognate interaction of virus-specific CD4+ helper T cells with virus-infected B cells may yield to hypergammaglobulinemia and autoantibody secretion in mice.21 It is therefore possible that a similar process operates in hepatitis C because HCV sequences are found in B cells,22 and that chronic HCV infection is associated with hypergammaglobulinemia, autoantibodies, and MC-linked disorders.    Acknowledgements   We acknowledge Marita Andreu and Hélène Trébéden-Nègre for their help; David Antonelli, Véronique Bon-Durand, Marie-Christine Burland, and Christiane Lourtau for technical assistance; and Benoit Salomon and José Cohen for helpful discussions.    Footnotes   Submitted September 3, 2003; accepted November 13, 2003. Prepublished online as Blood First Edition Paper, December 18, 2003; DOI 10.1182/blood-2003-07-2598. Supported by Agence Nationale de Recherche contre le SIDA, Centre National de la Recherche Scientifique, Faculté de Médecine Pitié-Salpêtrière, and Assistance Publique-Hôpitaux de Paris. O.B. and D.S. contributed equally to this study. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: David Klatzmann, Hôpital Pitié-Salpêtrière, 47 bd de l'hôpital, F-75013 Paris, France; e-mail: david.klatzmann{at}chups.jussieu.fr.    References Top Abstract Introduction Patients and methods Results Discussion References   Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2002;14: 29-35.[CrossRef][Medline] [Order article via Infotrieve] Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994;106: 1291-1300.[Medline] [Order article via Infotrieve] Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood. 1998;91: 2062-2066.[Abstract/Free Full Text] Cacoub P, Renou C, Kerr G, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum. 2001;44: 2118-2124.[CrossRef][Medline] [Order article via Infotrieve] Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155: 1151-1164.[Abstract] Salomon B, Lenschow D-J, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12: 431-440.[CrossRef][Medline] [Order article via Infotrieve] Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk A-H. Identification and functional characterization of human CD4(+)CD25(+)T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193: 1285-1294.[Abstract/Free Full Text] Levings M-K, Sangregorio R, Roncarolo M-G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193: 1295-1302.[Abstract/Free Full Text] Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193: 1303-1310.[Abstract/Free Full Text] Baecher-Allan C, Brown J-A, Freeman G-J, Hafler D-A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167: 1245-1253.[Abstract/Free Full Text] Ng W-F, Duggan P-J, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98: 2736-2744.[Abstract/Free Full Text] Kukreja A, Cost G, Marker J, et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest. 2002;109: 131-140.[CrossRef][Medline] [Order article via Infotrieve] Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33: 215-223.[CrossRef][Medline] [Order article via Infotrieve] Putman A-L, Vendrame F, Gottlieb P-A. Characterization of CD4+CD25hi T cells in human type 1 diabetes [abstract]. Clin Immunol. 2003;S1: 177a. Crispin J-C, Martinez A, Alcocer-Varela J. CD4+CD25+ T cells are decreased in patients with systemic lupus erythematosus [abstract]. Clin Immunol. 2003;S1: 177a. Viglietta V, Baecher-Allan C-M, Hafler D-A. CD4+CD25+ regulatory T cells have reduced function in patients with multiple sclerosis [abstract]. Clin Immunol. 2003;S1: 175a. Levings M-K, Sangregorio R, Sartirana C, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med. 2002;196: 1335-1346.[Abstract/Free Full Text] Jung T-M, Gallatin W-M, Weissman I-L, Dailey M-O. Down-regulation of homing receptors after T cell activation. J Immunol. 1988;141: 4110-117.[Abstract] Thornton A-M, Shevach E-M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164: 183-190.[Abstract/Free Full Text] Bennett C-L, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27: 20-21.[CrossRef][Medline] [Order article via Infotrieve] Hunziker L, Recher M, Macpherson A-J, et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol. 2003;4: 343-349.[CrossRef][Medline] [Order article via Infotrieve] Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91: 3841-3849.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. Kotsianidis, E. Nakou, I. Bouchliou, A. Tzouvelekis, E. Spanoudakis, P. Steiropoulos, I. Sotiriou, V. Aidinis, D. Margaritis, C. Tsatalas, et al. Global Impairment of CD4+CD25+FOXP3+ Regulatory T Cells in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1121 - 1130. [Abstract] [Full Text] [PDF] J. Liu, N. Gong, X. Huang, A. D. Reynolds, R. L. Mosley, and H. E. Gendelman Neuromodulatory Activities of CD4+CD25+ Regulatory T Cells in a Murine Model of HIV-1-Associated Neurodegeneration J. Immunol., March 15, 2009; 182(6): 3855 - 3865. [Abstract] [Full Text] [PDF] D-A Landau, M Rosenzwajg, D Saadoun, D Klatzmann, and P Cacoub The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders Ann Rheum Dis, March 1, 2009; 68(3): 337 - 344. [Abstract] [Full Text] [PDF] M. Korporal, J. Haas, B. Balint, B. Fritzsching, A. Schwarz, S. Moeller, B. Fritz, E. Suri-Payer, and B. Wildemann Interferon Beta-Induced Restoration of Regulatory T-Cell Function in Multiple Sclerosis Is Prompted by an Increase in Newly Generated Naive Regulatory T Cells Arch Neurol, November 1, 2008; 65(11): 1434 - 1439. [Abstract] [Full Text] [PDF] M. Bonelli, A. Savitskaya, K. von Dalwigk, C. W. Steiner, D. Aletaha, J. S. Smolen, and C. Scheinecker Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE) Int. Immunol., July 1, 2008; 20(7): 861 - 868. [Abstract] [Full Text] [PDF] D. Saadoun, M. Rosenzwajg, D. Landau, J. C. Piette, D. Klatzmann, and P. Cacoub Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis Blood, June 1, 2008; 111(11): 5334 - 5341. [Abstract] [Full Text] [PDF] M Bonelli, K von Dalwigk, A Savitskaya, J S Smolen, and C Scheinecker Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis Ann Rheum Dis, May 1, 2008; 67(5): 664 - 671. [Abstract] [Full Text] [PDF] L. C. Ndhlovu, C. P. Loo, G. Spotts, D. F. Nixon, and F. M. Hecht FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection J. Leukoc. Biol., February 1, 2008; 83(2): 254 - 262. [Abstract] [Full Text] [PDF] V. H. Nguyen, S. Shashidhar, D. S. Chang, L. Ho, N. Kambham, M. Bachmann, J. M. Brown, and R. S. Negrin The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation Blood, January 15, 2008; 111(2): 945 - 953. [Abstract] [Full Text] [PDF] S. Li, E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer Natural Regulatory T Cells and Persistent Viral Infection J. Virol., January 1, 2008; 82(1): 21 - 30. [Full Text] [PDF] V. Racanelli, M. A. Frassanito, P. Leone, C. Brunetti, S. Ruggieri, and F. Dammacco Bone Marrow of Persistently Hepatitis C Virus-Infected Individuals Accumulates Memory CD8+ T Cells Specific for Current and Historical Viral Antigens: A Study in Patients with Benign Hematological Disorders J. Immunol., October 15, 2007; 179(8): 5387 - 5398. [Abstract] [Full Text] [PDF] D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation Rheumatology, August 1, 2007; 46(8): 1234 - 1242. [Abstract] [Full Text] [PDF] J. Haas, B. Fritzsching, P. Trubswetter, M. Korporal, L. Milkova, B. Fritz, D. Vobis, P. H. Krammer, E. Suri-Payer, and B. Wildemann Prevalence of Newly Generated Naive Regulatory T Cells (Treg) Is Critical for Treg Suppressive Function and Determines Treg Dysfunction in Multiple Sclerosis J. Immunol., July 15, 2007; 179(2): 1322 - 1330. [Abstract] [Full Text] [PDF] D. Holmes, G. Knudsen, S. Mackey-Cushman, and L. Su FoxP3 Enhances HIV-1 Gene Expression by Modulating NF{kappa}B Occupancy at the Long Terminal Repeat in Human T Cells J. Biol. Chem., June 1, 2007; 282(22): 15973 - 15980. [Abstract] [Full Text] [PDF] I. J. Suffia, S. K. Reckling, C. A. Piccirillo, R. S. Goldszmid, and Y. Belkaid Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens J. Exp. Med., March 20, 2006; 203(3): 777 - 788. [Abstract] [Full Text] [PDF] M. Miyara, Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, D. Nochy, P. Debre, J.-C. Piette, and G. Gorochov Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus J. Immunol., December 15, 2005; 175(12): 8392 - 8400. [Abstract] [Full Text] [PDF] M. R. Nicolls, L. Taraseviciene-Stewart, P. R. Rai, D. B. Badesch, and N. F. Voelkel Autoimmunity and pulmonary hypertension: a perspective Eur. Respir. J., December 1, 2005; 26(6): 1110 - 1118. [Abstract] [Full Text] [PDF] E. Zorn, H. T. Kim, S. J. Lee, B. H. Floyd, D. Litsa, S. Arumugarajah, R. Bellucci, E. P. Alyea, J. H. Antin, R. J. Soiffer, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease Blood, October 15, 2005; 106(8): 2903 - 2911. [Abstract] [Full Text] [PDF] H. W. Lim, P. Hillsamer, A. H. Banham, and C. H. Kim Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells J. Immunol., October 1, 2005; 175(7): 4180 - 4183. [Abstract] [Full Text] [PDF] D. Wolf, K. Hochegger, A. M. Wolf, H. F. Rumpold, G. Gastl, H. Tilg, G. Mayer, E. Gunsilius, and A. R. Rosenkranz CD4+CD25+ Regulatory T Cells Inhibit Experimental Anti-Glomerular Basement Membrane Glomerulonephritis in Mice J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1360 - 1370. [Abstract] [Full Text] [PDF] L. A. Ormandy, T. Hillemann, H. Wedemeyer, M. P. Manns, T. F. Greten, and F. Korangy Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma Cancer Res., March 15, 2005; 65(6): 2457 - 2464. [Abstract] [Full Text] [PDF] A. Balandina, S. Lecart, P. Dartevelle, A. Saoudi, and S. Berrih-Aknin Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis Blood, January 15, 2005; 105(2): 735 - 741. [Abstract] [Full Text] [PDF] B. T. Rouse and S. Suvas Regulatory Cells and Infectious Agents: Detentes Cordiale and Contraire J. Immunol., August 15, 2004; 173(4): 2211 - 2215. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2003-07-2598v1 103/9/3428    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Boyer, O. Articles by Klatzmann, D. Search for Related Content PubMed PubMed Citation Articles by Boyer, O. Articles by Klatzmann, D. Related Collections Immunobiology Clinical Trials and Observations Social Bookmarking                   What's this?

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020